Therapy of Breast Tumor Cells Overexpressing c-cerbB-2/neu
Abstract
Two major independent barriers against the successful therapy of breast cancer are mutation of the tumor suppressor p53 gene and overexpression of the c-erbB-2/neu gene. However, there is little or no information on how, if at all, these molecular defects together influence therapeutic outcome. Of further concern is the absence of any therapeutic agents that could be used against both defects. The present research project was proposed to address these limitations. The results from this project indicate that both p53 (wild-type and mutant) and overexpression of c-erbB-2/neu lead to cisplatin resistance, and that the resistance due to wild-type p53 and c-erbB-2/neu overexpression can be circumvented by DACH-acetato-Pt.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2000
- Accession Number
- ADA389281
Entities
People
- Zahid H. Siddik
Organizations
- The University of Texas MD Anderson Cancer Center